510(k) device
cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test
Roche Molecular Systems, Inc. · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision Apr 25, 2025, newest Apr 25, 2025COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "cobas liat"
MAUDE reports
3,028
Brand "cobas liat", since 2015
PubMed studies
81
Mentioning "cobas liat"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K243400 · Decided Apr 25, 2025 · 176 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "cobas liat", any status and sponsor, newest update first.
No registered device study names "cobas liat".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "cobas liat", and for the whole product code for context.
This brand
3,028 reports: 3,027 malfunction, 0 injury, 1 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG
2243471-2025-01283 · Received Apr 25, 2025 · Event dated Mar 24, 2025
Device type: Covid-19 Multi-Analyte Respiratory Panel Nucleic Acid Devices (QLT)
Device problem as coded: Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "cobas liat"[tiab]. The summary above synthesizes these.
- Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in Nasal Samples.
Akashi Y, Horie M, Kiyotaki J, et al. · Mol Diagn Ther · 2022Research Support, Non-U.S. Gov't
- Clinical performance of the Roche Cobas Liat SARS-CoV-2 & influenza A/B assay: A systematic review and meta-analysis.
Chang E, Jeon K, Lee N, et al. · J Clin Virol · 2024Meta-Analysis, Systematic Review
- Comparing the cobas Influenza A/B Nucleic acid test for use on the cobas Liat System (Liat) with rapid antigen tests for clinical management of Japanese patients at the point of care.
Mikamo H, Koizumi Y, Yamagishi Y, et al. · PLoS One · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location.
Van Der Pol B, Arcenas R, Boraas C, et al. · J Clin Microbiol · 2025Multicenter Study, Observational Study
- Evaluation of cobas® Liat® Cdiff, STANDARDࡊ M10 C. difficile and Xpert® C. difficile BT assays for rapid detection of toxigenic Clostridioides difficile.
Suominen J, Korhonen S, Kutvonen H, et al. · J Microbiol Methods · 2024Evaluation Study, Comparative Study
- Comparison of CovidNudge and Cobas® Liat® PCR point of care tests for the diagnosis of SARS-CoV-2. Assessment of test agreement and usability of the CovidNudge.
Poole H, Lorenzo YSP, Jardine D, et al. · Diagn Microbiol Infect Dis · 2025Comparative Study
- Evaluation of the cobas Liat detection test for SARS-CoV-2 and influenza viruses following the emergence of the SARS-CoV-2 Omicron variant.
Park K, Sung H, Kim MN · Diagn Microbiol Infect Dis · 2023
- Testing the limits of multiplex respiratory virus assays for SARS-CoV-2 at high cycle threshold values: Comparative performance of cobas 6800/8800 SARS-CoV-2 & Influenza A/B, Xpert Xpress SARS-CoV-2/Flu/RSV, and cobas Liat SARS-CoV-2 & Influenza A/B.
Matic N, Lawson T, Ritchie G, et al. · J Assoc Med Microbiol Infect Dis Can · 2024
- Clinical Performance of the Point-of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study.
Hansen G, Marino J, Wang ZX, et al. · J Clin Microbiol · 2021Evaluation Study, Multicenter Study
- Portable molecular diagnostic instruments in microbiology: current status.
Zidovec Lepej S, Poljak M · Clin Microbiol Infect · 2020Review
- Comparing the Cobas Liat Influenza A/B and respiratory syncytial virus assay with multiplex nucleic acid testing.
Gosert R, Naegele K, Hirsch HH · J Med Virol · 2019Comparative Study, Evaluation Study
Other devices of this type
Also filed under product code QOF.
- Xpert Xpress CoV-2/Flu plusCepheid® · 510(k) 2026
- BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel MiniBiofire Diagnostics, LLC · 510(k) 2025
- QIAstat-Dx Respiratory Panel PlusQIAGEN GmbH · 510(k) 2025
- Panther Fusion SARS-CoV-2/Flu A/B/RSV assayHologic, Inc. · 510(k) 2024
- BIOFIRE Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics · De Novo 2026
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 SystemsRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.